Standout Papers

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-bli... 2017 2026 2020 2023 519
  1. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial (2017)
    Stewart J. Tepper, Messoud Ashina et al. The Lancet Neurology

Immediate Impact

1 from Science/Nature 74 standout
Sub-graph 1 of 18

Citing Papers

Trigeminal ganglion neurons are directly activated by influx of CSF solutes in a migraine model
2024 StandoutScience
A Monoclonal Antibody to PACAP for Migraine Prevention
2024 Standout
16 intermediate papers

Works of David Doležil being referenced

A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention
2020
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
2017 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
David Doležil 867 637 99 329 27 943
Hille Koppen 739 460 118 228 40 968
Yngve Hallström 776 479 133 255 11 926
N. T. Mathew 697 453 162 383 23 967
Jo Bonner 749 510 62 288 11 833
Davinia Larrosa 719 446 206 320 34 874
J LANCE 643 398 131 348 22 855
J. A. Klapper 826 461 47 359 17 886
Kevin Shields 673 483 85 363 13 852
G Zanchin 849 543 137 330 61 1.0k
R. Allan Purdy 770 494 112 334 38 1.0k

All Works

Loading papers...

Rankless by CCL
2026